Pulmonary Embolism Drugs Industry - Regional Synopsis
North American Market Forecast
The North American pulmonary embolism drugs market is anticipated to account for majority share by the end of 2037. The market growth is propelled by rising healthcare expenditure backed by escalating government spending to develop healthcare services. According to a report by the World Health Organization (WHO), as of 2018, the per capita healthcare expenditure of North America is valued at USD 10,050.279. Moreover, the presence of major pharmaceutical companies in the region will boost the market growth.
APAC Market Statistics
The Asia Pacific pulmonary embolism drugs market is predicted to observe massive growth during the forecast period, impelled by high prevalence of cancer in the region backed by growing government initiatives to launch and support programs to provide medical services for people living with cancer. For instance, in 2020, approximately 150 thousand people were estimated to be living with cancer in the Asia Pacific along with the high geriatric population, both of which are major causes of pulmonary embolism.
Europe Market Forecast
The Europe pulmonary embolism drugs market is set to hold a notable share by 2037. Factors such as, a higher prevalence of cancer in the region and higher demand for healthcare solution backed by increasing geriatric population will propel the market revenue. Moreover, the surge in research & development of pulmonary embolism drugs in the region will drive the market growth.
